33 reactions · 13 shares | Myeloma Awareness Week is coming up soon!...

Wonderful news for the myeloma community today as The National Institute for Health and Care Excellence (NICE) has recommended the use of lenalidomide as a maintenance treatment for newly diagnosed myeloma patients in England and Wales who are eligible for high-dose therapy and stem cell transplantation (HDT-SCT). This is the first maintenance treatment for myeloma to be made available through the NHS and is currently considered the global gold standard for HDT-SCT eligible patients. Following a

Multiple myeloma is a blood cancer that most often occurs in people over age 45. It's the second-most common blood cancer and the most common blood cancer in Black people. Right now, there is no cure for the disease. But as Dr. Joselle Cook, a Mayo Clinic hematologist, explains, recent advances in treatment are helping people live longer. Learn more: https://mayocl.in/48QiIAz | Mayo Clinic